Systematic Intravenous Administration of Autologous Mesenchymal Stem Cells Is Safe
Journal of Clinical Medicine · 07.12.2024 · 13 (23) · 7460
DOI: 10.3390/jcm13237460 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 07.12.2024. Verfasst von Takaaki Matsuoka und 3 weiteren Autor:innen. Beteiligte Einrichtung: Omotesando HELENE Clinic, 5-9-15-3F, Minami Aoyama, Minato City, Tokyo 1070062, Japan. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Mesenchymal stem cells (MSCs) have drawn significant attention for their regenerative potential and therapeutic applicability across a range of conditions, including cardiovascular diseases and age-related frailty. Despite extensive preclinical studies, there remain gaps in understanding the long-term safety and efficacy of MSC therapy in humans. This study aimed to assess the safety of intravenous MSC administration, evaluate the mean major adverse cardiac and cerebrovascular event (MACCE)-free period, and identify potential risk factors for MACCE development in patients receiving MSC therapy for various indications.
Methods
A retrospective observational study was conducted on 2504 patients (mean age: 54.09 ± 11.65 years) who received intravenous adipose-derived MSC (AD-MSC) therapy between October 2014 and December 2023 at the Omotesando Helene Clinic, Tokyo, Japan. Patients received MSC doses ranging from 100 million to 2 billion cells, with the majority receiving 1–2 billion cells per treatment. Statistical analyses included multivariate Cox proportional hazards regression and Kaplan–Meier survival analysis to evaluate MACCE risk factors and event-free duration.
Results
Over the follow-up period, the MACCE rate was exceptionally low at 0.2%. Multivariate analysis identified age as a significant risk factor for MACCE (hazard ratio: 1.127; 95% CI: 1.0418–1.219; p = 0.0029), while sex and MSC dose showed no significant association. Minor adverse events occurred in 0.8% of patients, with no severe adverse events reported. The study found MSC therapy to be safe, with a low adverse event rate and minimal risk of MACCE.
Conclusions
This study demonstrates the safety of intravenous MSC therapy in a large cohort of patients, with a low incidence of MACCE and minimal adverse effects. Age was the only significant predictor of MACCE risk. Further prospective randomized studies are needed to validate these findings and explore the potential of MSC therapy in reducing MACCE risk and improving clinical outcomes across diverse indications.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Omotesando HELENE Clinic, 5-9-15-3F, Minami Aoyama, Minato City, Tokyo 1070062, Japan.
ORCID-Profile: Takaaki Matsuoka
Zitieren
APA
Matsuoka, T., Itohara, T., Hara, Y., & Kobayashi, N. (2024). Systematic Intravenous Administration of Autologous Mesenchymal Stem Cells Is Safe. Journal of Clinical Medicine, 13(23), 7460. https://doi.org/10.3390/jcm13237460
Vancouver
Matsuoka T, Itohara T, Hara Y, Kobayashi N. Systematic Intravenous Administration of Autologous Mesenchymal Stem Cells Is Safe. Journal of Clinical Medicine. 2024;13(23):7460. doi:10.3390/jcm13237460
BibTeX
@article{Matsuoka2024,
author = {Matsuoka, Takaaki and Itohara, Takaaki and Hara, Yurie and Kobayashi, Nana},
title = {Systematic Intravenous Administration of Autologous Mesenchymal Stem Cells Is Safe},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {23},
pages = {7460},
doi = {10.3390/jcm13237460}
}
EUVIMED